OR WAIT null SECS
A study compared mortality and major adverse cardiovascular events in patients with type 2 diabetes prescribed metformin or insulin.
A retrospective cohort study published in The Lancet Diabetes and Endocrinology sought to look at the association between insulin dose and mortality and major adverse cardiovascular events in patients with T2DM.
The study was drawn from primary care records from the UK-based Clinical Practice Research Datalink that identified new users of metformin and those who had a new prescription for insulin.
According to the authors, the take-home message is, “The result from the study reassures both patients and physicians of the overall safety and absence of major cardiovascular harms of insulin in the treatment of type 2 diabetes.”